Tags

Type your tag names separated by a space and hit enter

Suppression of ongoing experimental allergic encephalomyelitis (EAE) in Lewis rats: synergistic effects of myelin basic protein (MBP) peptide 68-86 and IL-4.
Clin Exp Immunol. 2000 Jun; 120(3):526-31.CE

Abstract

Mucosal myelin autoantigen administration effectively prevented EAE, but mostly failed to treat ongoing EAE. Patients with multiple sclerosis (MS), for which EAE is considered an animal model, did not benefit from oral treatment with bovine myelin. We anticipated that autoantigen, administered together with a cytokine that counteracts Th1 cell responses, might ameliorate Th1-driven autoimmune disease, and that nasal administration might considerably reduce the amounts of antigen + cytokine needed for treatment purposes. Lewis rats with EAE actively induced with myelin basic protein peptide (MBP 68-86) and Freund's complete adjuvant (FCA), received from day 7 post-immunization, i.e. after T cell priming had occurred, 120 microg MBP 68-86 + 100 ng IL-4 per rat per day for 5 consecutive days. These rats showed later onset, lower clinical scores, less body weight loss and shorter EAE duration compared with rats receiving MBP 68-86 or IL-4 only, or PBS. EAE amelioration was associated with decreased infiltration of ED1+ macrophages and CD4+ T cells within the central nervous system, and with decreased interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) and enhanced IL-4, IL-10 and transforming growth factor-beta (TGF-beta) responses by lymph node cells. Simultaneous administration of encephalitogenic peptide + IL-4 by the nasal route thus suppressed ongoing EAE and induced IL-4, IL-10 and TGF-beta-related regulatory elements.

Authors+Show Affiliations

Units of Experimental Neurobiology and Neuroimmunology, Division of Neurology, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10844533

Citation

Xu, L Y., et al. "Suppression of Ongoing Experimental Allergic Encephalomyelitis (EAE) in Lewis Rats: Synergistic Effects of Myelin Basic Protein (MBP) Peptide 68-86 and IL-4." Clinical and Experimental Immunology, vol. 120, no. 3, 2000, pp. 526-31.
Xu LY, Huang YM, Yang JS, et al. Suppression of ongoing experimental allergic encephalomyelitis (EAE) in Lewis rats: synergistic effects of myelin basic protein (MBP) peptide 68-86 and IL-4. Clin Exp Immunol. 2000;120(3):526-31.
Xu, L. Y., Huang, Y. M., Yang, J. S., Van Der Meide, P. H., Link, H., & Xiao, B. G. (2000). Suppression of ongoing experimental allergic encephalomyelitis (EAE) in Lewis rats: synergistic effects of myelin basic protein (MBP) peptide 68-86 and IL-4. Clinical and Experimental Immunology, 120(3), 526-31.
Xu LY, et al. Suppression of Ongoing Experimental Allergic Encephalomyelitis (EAE) in Lewis Rats: Synergistic Effects of Myelin Basic Protein (MBP) Peptide 68-86 and IL-4. Clin Exp Immunol. 2000;120(3):526-31. PubMed PMID: 10844533.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Suppression of ongoing experimental allergic encephalomyelitis (EAE) in Lewis rats: synergistic effects of myelin basic protein (MBP) peptide 68-86 and IL-4. AU - Xu,L Y, AU - Huang,Y M, AU - Yang,J S, AU - Van Der Meide,P H, AU - Link,H, AU - Xiao,B G, PY - 2000/6/9/pubmed PY - 2000/7/6/medline PY - 2000/6/9/entrez SP - 526 EP - 31 JF - Clinical and experimental immunology JO - Clin. Exp. Immunol. VL - 120 IS - 3 N2 - Mucosal myelin autoantigen administration effectively prevented EAE, but mostly failed to treat ongoing EAE. Patients with multiple sclerosis (MS), for which EAE is considered an animal model, did not benefit from oral treatment with bovine myelin. We anticipated that autoantigen, administered together with a cytokine that counteracts Th1 cell responses, might ameliorate Th1-driven autoimmune disease, and that nasal administration might considerably reduce the amounts of antigen + cytokine needed for treatment purposes. Lewis rats with EAE actively induced with myelin basic protein peptide (MBP 68-86) and Freund's complete adjuvant (FCA), received from day 7 post-immunization, i.e. after T cell priming had occurred, 120 microg MBP 68-86 + 100 ng IL-4 per rat per day for 5 consecutive days. These rats showed later onset, lower clinical scores, less body weight loss and shorter EAE duration compared with rats receiving MBP 68-86 or IL-4 only, or PBS. EAE amelioration was associated with decreased infiltration of ED1+ macrophages and CD4+ T cells within the central nervous system, and with decreased interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) and enhanced IL-4, IL-10 and transforming growth factor-beta (TGF-beta) responses by lymph node cells. Simultaneous administration of encephalitogenic peptide + IL-4 by the nasal route thus suppressed ongoing EAE and induced IL-4, IL-10 and TGF-beta-related regulatory elements. SN - 0009-9104 UR - https://www.unboundmedicine.com/medline/citation/10844533/Suppression_of_ongoing_experimental_allergic_encephalomyelitis__EAE__in_Lewis_rats:_synergistic_effects_of_myelin_basic_protein__MBP__peptide_68_86_and_IL_4_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0009-9104&date=2000&volume=120&issue=3&spage=526 DB - PRIME DP - Unbound Medicine ER -